BBIO BridgeBio Pharma, Inc.
$69.37▲ +1.79%
Healthcare
Other
After hours
$69.37▲ +0.00%
Oct 27, 4:17 PM ET
Volume 2.04M
Avg Volume (10D) 2.54M
Key Metrics & Fundamentals
Market Cap
$13.56B
P/E Ratio
–
Div Yield
0.00%
52W Range
60.22 - 93.42
% vs 50 MA
-2.21%
% vs 200 MA
-4.75%
RSI-14
55.1
MACD Histogram
+0.7100
Beta (1Y vs SPY)
0.99
Free Cash Flow
-$71.54M
Gross Rev
$243.68M
Gross Profit
$228.63M
EBITDA
-$105.80M
COGS
$15.05M
Operating Exp
$335.71M
Operating Income
-$107.08M
EBIT
-$107.08M
Pretax Income
-$155.89M
Net Income
-$152.22M
EPS (Diluted)
-0.78
Price & Volume History
Loading chart…
Recent News
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
GlobeNewswire · Oct 22, 2026 7:30 AM ET
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Zacks · Oct 21, 2026 8:06 AM ET
What BridgeBio Pharma Doubters Missed
Simply Wall St. · Oct 20, 2026 11:12 AM ET
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Zacks · Oct 20, 2026 9:30 AM ET
BridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?
Simply Wall St. · Oct 20, 2026 7:15 AM ET
Where Does BridgeBio Pharma (BBIO) Value Sit After Trial Wins?
Simply Wall St. · Oct 20, 2026 6:11 AM ET
How Pipeline Progress Will Impact BridgeBio Pharma (BBIO) Investors
Simply Wall St. · Oct 20, 2026 5:17 AM ET
BridgeBio Pharma (BBIO) Unveils Acoramidis Data As Rare Disease Pipeline Nears Key Reviews
Simply Wall St. · Oct 20, 2026 4:16 AM ET
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires · Oct 19, 2026 11:42 AM ET
BofA Securities Lowers Price Target on BridgeBio Pharma to $102 From $104, Maintains Buy Rating
MT Newswires · Oct 19, 2026 7:57 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See BBIO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.